Sponsored by
I am honored to join the GBM Drug Discovery Group at Duke.
Dr. Al Musella, president of the Musella Foundation for Brain Tumor Research & Information, Inc, has been named as Adviser to the Glioblastoma Drug Discovery Group at Duke. This group is trying to find the cure of brain tumors in a new way:
Each patient’s tumor will be subjected to detailed proteomic and genomic analyses to identify the molecular machinery driving its growth. From this information, we will identify a list of drugs that have the potential to block the specific growth-promoting molecular machinery. These drugs will be tested in preclinical models (xenografts and stem cells) developed from the patient’s tumor, as these models retain the molecular machinery of the original tumor. Drugs found to be effective in the patient’s-derived preclinical models will be given to the patient.
The Musella Foundation and the National Institutes of Health are funding the project.
About the Musella Foundation: The Musella Foundaton For Brain Tumor Research & Information, Inc, a 501(C)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. For brain tumor information, go to our website at http://virtualtrials.com
About the GBM Drug Discovery Group at Duke: The GBM Drug Discovery Group was created to To modify the current standard of care for Glioblastoma (GBM) patients to decrease tumor recurrence and increase patient survival. See GBM.DUKE.EDU for details!